Global Locations

Gefitinib



Chemical Properties of 'Gefitinib'

CAT No. :

CS-O-11657
CAS Registry No. : 184475-35-2
Category : API Standards
Molecular Weight: 446.90
Molecular Formula : C₂₂H₂₄ClFN₄O₃



OTHER INFORMATION of 'Gefitinib'
Purity : Not less than 95%
Therapeutic : Anti-Cancer / Oncology
Purity : Not less than 95%
Therapeutic : Anti-Cancer / Oncology
IUPAC Name :N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
Applicationnotes :Gefitinib is an antineoplastic.
Synonym :Not available
References :"Anderson; N,G,; et al,: Int, J, Cancer; 94; 774 (2001); Hirata; A,; et al,: Cancer Res,; 62; 2554 (2002); Kris; M,G,; et al,: J, Am, Med, Assoc,; 290; 2149 (2003); Tamura; K,; et al,: Expert Opin, Pharmacother,; 6; 985 (2005);"
Smileys :COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Appearance :Off white to white solid
Solubility :Sparingly soluble (
Use Classification :Human drugs -> Iressa -> EMA Drug Category
Hazard Class :Acute Tox. 4 (100%)
EC Number :643-034-7
UNII :S65743JHBS
NCI Thesaurus Code :C1855
RXCUI :328134
MeSH Entry Terms :gefitinib
Other Synonyms :Gefitinib
Removed Synonyms :Gefitini
Label Ingredient : GEFITINIB
NDC Code :0310-0482-30, 0310-0482-93, 73377-121-01
Metabolite Pathways :Gefitinib Action Pathway
Toxicity Summary :The acute toxicity of gefitinib up to 500 mg in clinical studies has been low. In non-clinical studies, a single dose of 12,000 mg/m2 (about 80 times the recommended clinical dose on a mg/m2 basis) was lethal to rats. Half this dose caused no mortality in mice. Symptoms of overdose include diarrhea and skin rash.
Hepatotoxicity :In large early clinical trials, elevations in serum aminotransferase levels occurred in 9% to 13% of patients treated with standard doses of gefitinib, and 2% to 4% of patients had to stop therapy because of elevations above 5 times the upper limit of normal. Serum enzyme elevations typically arise after 4 to 12 weeks of treatment with a hepatocellular pattern. Immunoallergic and autoimmune features have not been described, but rash is common in patients receiving gefitinib. Most cases of liver injury due to gefitinib in the literature have been minimally or not symptomatic, and the injury resolved within 1 to 2 months of stopping the drug. Restarting therapy was usually but not always followed by rapid recurrence of serum enzyme elevations, and corticosteroid therapy did not appear to prevent this recurrence. In some instances, lower doses were tolerated with minimal or no ALT elevations. Periodic monitoring of liver tests during therapy is recommended. Despite the frequency of serum aminotransferase elevations during gefitinib therapy, cases of clinically apparent liver injury with jaundice are rare. Cases of severe and fatal hepatotoxicity have been reported to the sponsor and monitoring of liver tests during therapy is recommended.
Drug Induced Liver Injury :gefitinib
Protein Binding :90% primarily to serum albumin and alpha 1-acid glycoproteins (independent of drug concentrations).
Exact Mass :446.1520965
InChI :InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InchIKey :XGALLCVXEZPNRQ-UHFFFAOYSA-N
Canonical SMILES :COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Isomeric SMILES :COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4
Product Description :Gefitinib is a member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer. It has a role as an epidermal growth factor receptor antagonist and an antineoplastic agent. It is an aromatic ether, a member of monochlorobenzenes, a member of monofluorobenzenes, a secondary amino compound, a tertiary amino compound, a member of quinazolines and a member of morpholines.
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back
Custom Duty : Applicable
Port of Loading : Canada
Expected Dispatch : 2-3 Weeks
Taxes : Not Applicable
Refund Policy : 30-days money back


More information about Gefitinib






This page contains information about Gefitinib , Gefitinib cas, Gefitinib synthesis, Gefitinib suppliers

What is Gefitinib ?
Gefitinib falls under API Standards of Gefitinib.Gefitinib is an antineoplastic.
What is the CAS Number of Gefitinib?
The CAS Number of Gefitinib is 184475-35-2
Who are the suppliers of Gefitinib?
CLEARSYNTH is a worldwide supplier of Gefitinib

List of Gefitinib API Standards

Looking for a discounted price or need more info for 'Gefitinib (CS-O-11657)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.

Looking for a discounted price or need more info for 'Gefitinib (CS-O-11657)' ?

If you are looking for Bulk purchase, Discounted Price, etc. please share your email and the exact quantity you are looking for, our team will respond to you within 30 mins with all the required information.